SPT Labtech Firefly Liquid Handling Platform
SPT Labtech this week launched the Firefly liquid handling platform for next-generation sequencing library prep. Firefly combines pipetting, dispensing, incubating, and shaking into a single platform. It features a 384-pipetting module and three or six dispense heads, and the pipetting operates in several configurations: 384, 96, columns of 16 (364 format), and columns of 8 (96 format), from 0.5 µL to 125 µL (extending to 50 µL with an optional adapter). The platform is fully application ready with prevalidated protocols for library preparation kits NEBNext Ultra II DNA; NEBNext Ultra II FS DNA; NEBNext Ultra II RNA; and Illumina DNA Prep with a rolling program of new validated protocols in development. In addition, a peer-to-peer cloud-based network will allow researchers to share their custom protocols and use SPT Labtech's validated tools.
New England Biolabs LyoPrime Luna RT-qPCR Master Mix
New England Biolabs has launched LyoPrime Luna RT-qPCR master mix, its first lyophilized reagent product since the acquisition of lyophilization R&D service company Fluorogenics in 2021.
The product enables a fast and simple resuspension with the addition of nuclease-free water, room-temperature shipping and storage, as well as a shelf life of two years at room temperature. It supports multiplexing of up to five targets and uses Luna WarmStart RT paired with Hot Start Taq to increase reaction specificity and robustness. The product's passive reference dye offers compatibility across a variety of instrument platforms, and it includes thermolabile UDG and dUTP to prevent carryover contamination as well as a non-fluorescent blue tracking dye for ease of pipetting.
OncoDNA OncoDeep Kit
OncoDNA has launched the OncoDeep kit, a disseminated version of its in-house OncoDeep cancer sequencing assay. According to the company, the kit offers a complete workflow solution incorporating Twist Bioscience's enrichment and library preparation solutions. The panel covers over 600 cancer biomarkers, and will be coupled with OncoDNA's data analysis and clinical interpretation tools. The test panel is optimized for the reliable analysis of somatic variants and translocations while also facilitating the measurement of complex genomic signatures such as homologous recombination deficiency, tumor mutational burden, microsatellite instability, and loss of heterozygosity. The kit is currently available for early access, with a full launch planned by the end of Q2 2022.
For more new products and services, please visit the New Products page on our website.